Last week @fda sends out clarification on who can and cannot compound #glp1 like #tirzeaptide and #semaglutide and this week ProRx 503b shuts down GLP 1 compounding while @martymakary is photographed holding bootleg # FDA July 2026 Peptide Meeting: What Patients Need to Know About Access, Approval, and Safety Meto blog FDA Removes 12 Peptides from 503A Category 2 : r us_pharmacies The FDA just changed the rules on peptides effective April 15, 2026. BPC 157, GHK Cu, MOTS C, and TB 500 have been removed from the Category 2 restricted compounding list. Here is what RFK Jr. & claimed regenerative peptides like BPC 157 The Niche